Pelabresib Plus Ruxolitinib Improves Signs of Underlying Myelofibrosis Pathobiology and Provides Clinical Benefit Over JAK Inhibitor Monotherapy By Ogkologos - March 25, 2025 900 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MANIFEST-2 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR A Combination of Talazoparib and Enzalutamide Prolongs OS in Unselected and... August 11, 2025 Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom... June 18, 2026 ¿Puede el uso de un microondas causar cáncer? April 7, 2022 Efficacy Outcomes of Olaparib in Patients with mCRPC with BRCA Alterations... November 21, 2023 Load more HOT NEWS What Cancer Survivors Should Know About Survivorship Research: Expert Perspectives Adjuvant Pembrolizumab Plus Chemotherapy Improves DFS in Patients with Newly-Diagnosed, High-Risk... Gilteritinib Improves Survival in AML with FLT3 Mutations Advanced MRI could help to differentiate aggressive and slower growing prostate...
